Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
N/A N=32 Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye
Dry Eye
Primary: The Percentage of Subjects at Month 3 With Corneal Sensitivity < 50 Millimeters (mm) at Any of the Locations Measured — 13; 13; 21.7; 13 Percentage of Subjects
Phase 4 N=79 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
Phase 4 N=180 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms
Dry Eye Syndromes · Cataract
Primary: Tear Break-Up Time (TBUT) in the Study Eye — 8.5; 6.6 Seconds
Phase 4 N=76 Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL
Cataract
Primary: Visual Acuity — 0.54; 0.06; 0.03; 0.04 logMAR
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
N/A N=80 Quatera 700 vs. Centurion
Cataract
Primary: Central Corneal Thickness — 572.8; 565.6 microns
Phase 4 N=80 Effect of Intraoperative Dexamethasone on Post-op Dry Eye
Dry Eye Syndromes
Primary: Evaluation of Intraoperative Use of Dexycu on Tear Film Osmolarity at 3 Weeks Postoperatively — 311.15; 316.3 mOsmol/L — p=<.01
Phase 3 N=378 Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Participants With ACC Count = 0 at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication — 48; 10 Participants — p=<0.001
Phase 2 N=37 A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
Post Surgical Ocular Inflammation
Primary: Assessment of Both Systemic and Ocular Adverse Events — 0; 3; 0; 0 Number of TEAE
Phase 3 N=241 OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Number of Participants With an Absence of Anterior Chamber Inflammation — 63; 25 participants
Phase 3 N=380 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
Ocular Infections, Irritations and Inflammations
Primary: Resolution of Anterior Chamber Cells — 48; 39; 19 Participants — p=.0024
N/A N=86 Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery
Dry Eye Syndromes
Primary: an Ocular Surface Disease Index (OSDI) Questionnaire That is Related to Dry Eye Severity. — 21.09; 23.00; 31.28; 20.31 scores on a scale — p=0.221
Phase 2 N=30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants
N/A N=11 Triamcinolone vs. Laser for Diabetic Macular Edema
DIABETIC MACULAR EDEMA
Primary: Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost.
N/A N=79 Patient Perception of Visual Distortions
Cataract · Astigmatism
Primary: Visual Distortion Symptoms — 0.89; 0.38; 0.64; 0.38 rating of visual distortion symptoms
Phase 3 N=438 OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Absence of Anterior Chamber Inflammation — 52.3; 31.1 percentage of total participants
N/A N=3,785 Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313
Posterior Capsule Opacification
Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes
N/A N=208 Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses
Cataract
Primary: Percentage of Participants Classified as Responders — 45.7; 2.1 percentage of participants
N/A N=84 Conventional Surgery vs. Verion/VerifEye
Cataract · Astigmatism
Primary: Residual Refractive Cylinder — 0.28; 0.33 Diopters
Phase 4 N=60 Visual Function After Bilateral Implantation of AcrySof® Toric
Visual Function
Primary: Uncorrected Visual Acuity (UCVA) — 0.06; 0.14 logMAR
N/A N=49 Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Pseudophakia · Inflammation
Primary: Investigate Clinical Outcomes for Intraocular Pressure After Treatment With Lotemax (Loteprednol Ophthalmic Solution) 0.5% QID in Subjects Who Have Undergone Cataract…
Phase 3 N=42 Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Post-surgical Cystoid Macular Edema (PSCME)
Primary: Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline — 10.6; 7.8; 13.1; 9.4 letters
Phase 2 N=91 Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
Inflammation
Primary: Anterior Chamber Cell: Categorical Cure — 18; 16; 6 Participants
Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105